Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by LongRoadon Jun 12, 2018 6:47pm
107 Views
Post# 28162490

RE:Looks that JG missed the boat

RE:Looks that JG missed the boatThese companies and GUD don't really have much in common, other than they are in pharma.

Knight's approach is vastly different.  Further, the current stock price doesn't tell you anything about the future success of the business. 

For example, ENDP who owns Paladin has no equity, lost $2.26 per share in its last quarter, owes over $8 billion, and generated $9 million dollars of cash after debt payments in the quarter.  Since almost all investors in this type of stock have no idea if under those circumstances the company will survive, any price appreciation is not based on fact, but rather hope or speculation.

GUD is simply boring compared to these companies... 

Bullboard Posts